Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics
{{output}}
The emergence of monoclonal antibody (MABs) drugs since the FDA approval of lecanemab has resulted in dramatic changes in the clinical approach and management of early-stage Alzheimer's disease (AD). Challenges with MAB adoption into clinical practice may var... ...
